Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model

Nuclear Medicine and Biology

Volumn 36, Issue 4, 2009, Pages 419-426

  Oh, Myungmi ^a   Tanaka, Takeshi ^a   Kobayashi, Masato ^a   Furukawa, Takako ^b   Mori, Tetsuya ^c   Kudo, Takashi ^a   Fujieda, Shigeharu ^a   Fujibayashi, Yasuhisa ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F FDG; 64Cu Cu ATSM; Clonogenic assay; Hypoxia; Proliferation

Indexed keywords

BROXURIDINE; DIACETYL BIS(N 4 METHYLTHIOSEMICARBAZONE) CU 64; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PIMONIDAZOLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELL HYPOXIA; CELL PROLIFERATION; CLONOGENIC ASSAY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; TUMOR CELL;

ANIMALS; ANOXIA; AUTORADIOGRAPHY; BROMODEOXYURIDINE; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; COPPER RADIOISOTOPES; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MICE; NITROIMIDAZOLES; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; STAINING AND LABELING; THIOSEMICARBAZONES;

EID: 67349100641     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.016     Document Type: Article

References (28)

1. Hammer S., To K.K., Yoo Y.G., Koshiji M., and Huang L.E. Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. Cell Cycle 6 (2007) 1919-1926
2. Wouters A., Pauwels B., Lardon F., and Vermorken J.B. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 12 (2007) 690-712
3. 4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 14 (2000) 323-328
4. Lewis J.S., McCarthy D.W., McCarthy T.J., Fujibayashi Y., and Welch M.J. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 40 (1999) 177-183
5. Fujibayashi Y., Cutler C.S., Anderson C.J., McCarthy D.W., Jones L.A., Sharp T., et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol 26 (1999) 117-121
6. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., and Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38 (1997) 1155-1160
7. Obata A., Kasamatsu S., Lewis J.S., Furukawa T., Takamatsu S., Toyohara J., et al. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nucl Med Biol 32 (2005) 21-28
8. 4-methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci USA 98 (2001) 1206-1211
9. Dehdashti F., Grigsby P.W., Mintun M.A., Lewis J.S., Siegel B.A., and Welch M.J. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55 (2003) 1233-1238
10. Chao K.S., Bosch W.R., Mutic S., Lewis J.S., Dehdashti F., Mintun M.A., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
11. Tanaka T., Furukawa T., Fujieda S., Kasamatsu S., Yonekura Y., and Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol 33 (2006) 743-750
12. Obata A., Yoshimoto M., Kasamatsu S., Naiki H., Takamatsu S., Kashikura K., et al. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. Nucl Med Biol 30 (2003) 529-534
13. 4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61 (2005) 1493-1502
14. Matsumoto K., Szajek L., Krishna M.C., Cook J.A., Seidel J., Grimes K., et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 30 (2007) 873-881
15. Scholzen T., and Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 182 (2000) 311-322
16. Hamacher K., Coenen H.H., and Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27 (1986) 235-238
17. Gratzner H.G. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 218 (1982) 414-415
18. Riccardi A., Danova M., and Ascari E. Bromodeoxyuridine for cell kinetic investigations in humans. Haematologica 73 (1988) 423-430
19. Ljungkvist A.S., Bussink J., Rijken P.F., Raleigh J.A., Denekamp J., and Van Der Kogel A.J. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 48 (2000) 1529-1538
20. 4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 15 (2001) 499-504
21. Moreno S.N., Mason R.P., Muniz R.P., Cruz F.S., and Docampo R. Generation of free radicals from metronidazole and other nitroimidazoles by Tritrichomonas foetus. J Biol Chem 258 (1983) 4051-4054
22. Arteel G.E., Thurman R.G., Yates J.M., and Raleigh J.A. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 72 (1995) 889-895
23. Arteel G.E., Thurman R.G., and Raleigh J.A. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 253 (1998) 743-750
24. Urruticoechea A., Smith I.E., and Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23 (2005) 7212-7220
25. van Dierendonck J.H., Keijzer R., van de Velde C.J., and Cornelisse C.J. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res 49 (1989) 2999-3006
26. Du Manoir S., Guillaud P., Camus E., Seigneurin D., and Brugal G. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 12 (1991) 455-463
27. Green S.L., Freiberg R.A., and Giaccia A.J. p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol Cell Biol 21 (2001) 1196-1206
28. Denko N.C., Green S.L., Edwards D., and Giaccia A.J. p53 checkpoint-defective cells are sensitive to X rays, but not hypoxia. Exp Cell Res 258 (2000) 82-91